ClinicaliQ Trial Snapshot
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06328608.
- What is being tested: PRX-102, a novel therapeutic agent, is being evaluated for safety and efficacy in the paediatric population (children and adolescents) with Fabry disease, a rare lysosomal storage disorder.
- Patient eligibility overview: The trial includes children and adolescents diagnosed with Fabry disease; specific age ranges, disease severity criteria, and prior treatment history will determine individual eligibility for enrolment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Eligibility Snapshot
- : * Participants with the provision of informed consent from their legal guardians * Boys and girls aged 2 to 7 years (Cohort A), 8 to 12 years (Cohort B), or 13 to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.